查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1981455

藥物發現資訊學市場：按組件、治療領域、應用、最終用戶和部署模式分類－2026-2032年全球市場預測

Drug Discovery Informatics Market by Component, Therapeutic Area, Application, End User, Deployment - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，藥物發現資訊學市場價值將達到 35.1 億美元，到 2026 年將成長到 38.8 億美元，到 2032 年將達到 69.5 億美元，複合年成長率為 10.21%。

主要市場統計數據
基準年 2025 35.1億美元
預計年份：2026年 38.8億美元
預測年份 2032 69.5億美元
複合年成長率 (%) 10.21%

藥物發現資訊學的發展以及組織為整合計算平台和服務而應採取的策略重點架構。

藥物資訊學融合了計算科學、生物學和轉化研究，重塑了治療假設的生成、檢驗和推進方式。生物資訊學和化學資訊學的創新正在拓展In Silico方法的範圍和精確度，使研究團隊能夠以前所未有的深度分析基因組、蛋白質組和化學領域。此外，相關服務能夠將平台輸出轉換為可操作的工作流程，並透過諮詢、系統整合和持續支持，確保模型輸出與實驗室執行之間的銜接。

識別技術、服務和管治的融合趨勢，這些趨勢正在重塑整個研究生態系統中的藥物發現資訊學和夥伴關係模式。

藥物發現資訊學領域正經歷著一場變革性的轉變，其驅動力來自調查方法的成熟、平台整合以及雲端原生運算範式的普及。基於多組體學資料集訓練的機器學習模型如今已常規地與基於物理的模擬相結合，分子對接、QSAR建模和虛擬篩檢技術的通量和預測精度也得到了顯著提升。此外，對可重複性和可解釋性的日益重視進一步強化了這些技術進步，促使供應商和研究團隊加強對Provence（一種模型檢驗框架）和透明性能基準的投入。

本研究評估了 2025 年與關稅相關的貿易變化將如何影響藥物研發專案中的供應商多元化、合約創新和策略部署選擇。

2025年美國關稅環境造成了多層次的商業性不確定性，將影響採購、供應商策略和國際合作。在硬體、專用運算設備和某些軟體相關服務與跨境貿易密切相關的領域，關稅促使各組織重新評估其籌資策略和整體參與成本。實際上，採購團隊正在擴大供應商範圍，納入國內供應商和區域合作夥伴，一些組織還在協商簽訂多年期契約，以應對未來關稅變化帶來的影響。

我們按組件、應用、部署模型、最終用戶和治療領域進行細分，以識別差異化的部署模式和策略機會領域。

細分市場分析闡明了功能和需求如何在組件、應用、部署模式、最終用戶和治療領域中分佈，揭示了不同的部署模式和功能缺口。從組件來看，市場由「服務」和「軟體」兩部分組成。 「服務」包括諮詢、系統整合、支援和維護等功能，這些功能彌合了平台功能與實驗室操作之間的差距。 「軟體」則分為生物資訊學和化學資訊學。在生物資訊學領域，基因組資訊學、蛋白質組學和轉錄組學分別反映了不同的數據模式和分析需求。同時，在化學資訊學領域，分子對接、QSAR建模和虛擬篩檢是支援化合物優先排序和虛擬先導化合物發現的融合方法。

本報告將揭示區域管理體制、人才庫和基礎設施現狀如何影響全球部署選擇、夥伴關係和合作模式。

區域趨勢，以及各自獨特的監管環境、人才儲備和基礎設施考量，正在影響各組織部署資訊學解決方案和建立夥伴關係的方式。在美洲，對轉化研究的大力投入、生物製藥公司總部的高度集中以及成熟的雲端運算和高效能運算（HPC）能力，正在推動整合生物資訊學和化學資訊學平台的快速普及。這種環境強調互通性和供應商生態系統，以支援學術機構和商業夥伴之間的複雜合作，並實現跨機構的端到端發現工作流程。

本分析探討了平台供應商、整合商、服務供應商和研究合作夥伴如何建構能力和合作夥伴關係，以提供端到端的藥物發現解決方案。

在藥物資訊學領域運作的公司正在平台開發、服務交付和整合夥伴關係展現出差異化的能力。成熟的軟體供應商專注於建立強大且檢驗的生物資訊學和化學資訊學工具鏈，並投資於模組化架構，使客戶能夠整合基因組學、蛋白質組學和分子建模的結果。同時，越來越多的專業公司正在利用機器學習和基於實體的模型來提高ADMET預測、虛擬篩檢和基於結構的藥物設計方面的預測性能，並經常與大型整合商合作，以服務企業客戶。

為了加快發現流程，領導者需要建立可互通的平台，平衡部署風險，並採取切實可行的策略措施來加強模型管治。

產業領導者應採取一系列切實有效的措施，調整組織能力以適應不斷變化的資訊學需求，並確保策略柔軟性。首先，應優先考慮互通架構和標準化資料模型，以便在無需大規模重新設計的情況下整合新工具。這將減少供應商鎖定，並加速跨職能工作流程。其次，應採用混合部署策略，兼顧本地資源的安全性和控制力以及雲端環境的彈性運算和協作優勢。這種方法允許團隊將敏感資料工作流程分配到託管環境中，同時利用公共雲端進行運算密集型模擬。

本文描述了一種混合方法研究途徑，該方法結合了相關人員訪談和二手研究，以得出檢驗的見解和明確的限制。

本分析的調查方法結合了多方面的質性研究和結構化的綜合分析，旨在得出引人注目且切實可行的見解。主要研究包括對製藥和生物技術公司、受託研究機構(CRO)、平台供應商和學術研究機構的關鍵相關人員進行訪談，重點關注採購行為、採用決策、整合挑戰和治療領域優先事項。這些訪談旨在了解從業人員對功能、挑戰和策略權衡的觀點，參與者包括計算科學家、研發 (R&D) 負責人和營運經理。

將調查方法、商業性和營運因素綜合起來，形成對電腦輔助藥物發現和轉化研究未來的洞察和結論。

累積分析凸顯了該領域的發展演變。調查方法的進步、平台的成熟以及商業性動態的轉變正在重塑藥物發現的概念化和實施方式。資訊學能力不再只是輔助工具，而是假設生成和候選化合物篩選的核心驅動力，軟體平台和服務之間的交互作用決定了組織將計算科學洞見轉化為實際應用的程度。商業性因素，例如區域和關稅方面的考量，對採購政策和部署架構施加了實際限制，而按應用和治療領域進行細分則有助於明確哪些投資領域能夠帶來最大的科學和營運回報。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 藥物發現資訊學市場：依組成部分分類

  • 服務
    • 諮詢
    • 一體化
    • 支援和維護
  • 軟體
    • 生物資訊學
      • 基因組資訊學
      • 蛋白質體學資訊學
      • 轉錄組學資訊學
    • 化學資訊學
      • 分子對接
      • QSAR建模
      • 虛擬篩檢

第9章：藥物發現資訊學市場：依治療領域分類

  • 心血管疾病
  • 感染疾病
  • 代謝性疾病
  • 神經科學
  • 腫瘤學

第10章 藥物發現資訊學市場：依應用領域分類

  • ADMET預測
    • 代謝預測
    • 藥物動力學預測
    • 毒性預測
  • 發現鉛
    • 高通量篩檢資訊學
    • 從爆款到爆款的資訊學
    • 虛擬篩檢資訊學
  • 分子建模與模擬
    • 分子動力學
    • QSAR建模
    • 結構設計
  • 目標識別
    • 基因組分析
    • 蛋白質體學分析
    • 目標檢驗資訊學

第11章 藥物發現資訊學市場：以最終用戶分類

  • 學術研究機構
  • 合約研究機構
  • 製藥和生物技術公司

第12章 藥物發現資訊學市場：依發展領域分類

  • 雲
  • 現場

第13章 藥物發現資訊學市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 藥物發現資訊學市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 藥物發現資訊學市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國藥物發現資訊學市場

第17章：中國藥物發現資訊市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • BioSolveIT GmbH
  • Certara, Inc.
  • Clarivate PLC
  • Dassault Systemes SE
  • Dotmatics Ltd
  • Genedata AG
  • InSilico Medicine
  • International Business Machines Corporation
  • Jubilant Biosys Ltd.
  • Optibrium Ltd
  • Oracle Corporation
  • PerkinElmer Inc.
  • Schrodinger, Inc.
  • TIBCO Software Inc.
Product Code: MRR-521BAA36EBB5

The Drug Discovery Informatics Market was valued at USD 3.51 billion in 2025 and is projected to grow to USD 3.88 billion in 2026, with a CAGR of 10.21%, reaching USD 6.95 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.51 billion
Estimated Year [2026] USD 3.88 billion
Forecast Year [2032] USD 6.95 billion
CAGR (%) 10.21%

Framing the evolution of drug discovery informatics and the strategic priorities organizations must adopt to integrate computational platforms and services

Drug discovery informatics sits at the nexus of computational science, biology, and translational research, reshaping how therapeutic hypotheses are generated, validated, and advanced. Innovations in bioinformatics and cheminformatics have expanded the scope and precision of in silico approaches, enabling research teams to interrogate genomic, proteomic, and chemical spaces with unprecedented depth. These capabilities are complemented by services that translate platform outputs into deployable workflows, with consulting, systems integration, and ongoing support ensuring continuity between model outputs and laboratory execution.

Across organizations, this convergence is driving a shift in operational models: software platforms that once served as niche tools are now integral to discovery pipelines, while service providers are embedding advanced analytics into end-to-end solutions. As a result, cross-functional teams composed of computational scientists, bench researchers, and data engineers are becoming standard, fostering rapid iteration between hypothesis generation and empirical validation. In this context, leaders must prioritize interoperability, data provenance, and lifecycle management of computational models to preserve scientific rigor while accelerating time-to-experimentation. Understanding these dynamics is essential for stakeholders seeking to align capabilities with strategic goals and to navigate the competitive landscape of platform vendors, integrators, and research institutions.

Identifying the converging technological, service, and governance trends reshaping drug discovery informatics and partnership models across the research ecosystem

The landscape of drug discovery informatics is undergoing a transformative shift driven by methodological maturation, platform integration, and the mainstreaming of cloud-native compute paradigms. Machine learning models trained on multi-omic datasets are now routinely coupled with physics-based simulations, while molecular docking, QSAR modeling, and virtual screening methods have improved in throughput and predictive value. These technical gains are reinforced by a growing emphasis on reproducibility and explainability, prompting vendors and research groups to invest in provenance, model validation frameworks, and transparent performance benchmarks.

Concurrently, services ecosystems have evolved to provide not only implementation support but also strategic advisory roles. Consulting teams increasingly help organizations assess the fit of bioinformatics and cheminformatics solutions against internal capabilities, and integration experts orchestrate data flows between laboratory information management systems, high-performance computing resources, and cloud environments. The rise of hybrid deployment options allows organizations to balance data sensitivity with scalability, enabling secure on-premise processing for protected datasets and public cloud bursts for compute-intensive simulations. Taken together, these developments are reshaping partnership models between technology providers, contract research organizations, and end users, creating new pathways for innovation while raising the bar for governance and interoperability.

Assessing how tariff-related trade shifts in 2025 are prompting supplier diversification, contractual innovation, and strategic deployment choices in discovery programs

The United States tariff environment in 2025 introduced layers of commercial uncertainty that ripple across procurement, supplier strategies, and international collaborations. Where hardware, specialized computational appliances, and certain software-linked services intersect with cross-border trade, tariffs have prompted organizations to reassess sourcing strategies and total cost of engagement. In practice, procurement teams have expanded supplier panels to include domestic vendors and regional partners, and some organizations have negotiated multi-year agreements to protect against further tariff volatility.

These adjustments have implications for research timelines and capital planning. R&D leaders are increasingly evaluating the tradeoffs between acquiring on-premise infrastructure and adopting cloud-based alternatives that mitigate hardware import exposure. Similarly, partnerships with contract research organizations and platform providers are being structured to share risk, with clauses that address tariff-related cost changes and delivery contingencies. In addition, tariff-driven supply chain realignments have intensified interest in regionalized data processing and storage, both to reduce exposure and to meet evolving regulatory obligations. Ultimately, the cumulative impact of tariffs is less a single cost shock and more a stimulus for strategic supplier diversification, contractual innovation, and accelerated adoption of deployment models that decouple computational capacity from geopolitically sensitive hardware supply chains.

Unpacking component, application, deployment, end-user, and therapeutic area segmentation to reveal differentiated adoption patterns and strategic opportunity spaces

Segmentation analysis clarifies how capabilities and demand are distributed across components, applications, deployments, end users, and therapeutic areas, revealing differentiated adoption patterns and capability gaps. By component, the market comprises Services and Software; Services encompasses consulting, systems integration, and support and maintenance functions that bridge the gap between platform capabilities and laboratory operations, while Software divides into Bioinformatics and Cheminformatics. Within Bioinformatics, genomics informatics, proteomics informatics, and transcriptomics informatics reflect distinct data modalities and analytic requirements; within Cheminformatics, molecular docking, QSAR modeling, and virtual screening represent convergent methods that support compound prioritization and virtual hit discovery.

Application segmentation highlights how analytical techniques are applied: ADMET prediction spans metabolism, pharmacokinetics, and toxicity prediction workflows that inform early attrition mitigation; lead discovery combines high-throughput screening informatics, hit-to-lead processing, and virtual screening informatics to accelerate candidate selection; molecular modeling simulation includes molecular dynamics, QSAR modeling, and structure-based design used to refine candidates; and target identification blends genomic and proteomic analyses with target validation informatics to prioritize biological hypotheses. Deployment choices manifest as cloud and on-premise models; cloud offerings differentiate across hybrid cloud, private cloud, and public cloud options, while on-premise deployments range from client-server to enterprise server implementations. End users include academic research institutes, contract research organizations, and pharmaceutical and biotechnology companies, each exhibiting unique procurement behaviors, risk tolerances, and demands for customization. Therapeutic area segmentation spans cardiovascular disease, infectious disease, metabolic disorders, neuroscience, and oncology, reflecting both scientific complexity and investment focus. Understanding these segments in an integrated manner enables targeted capability development and market-facing strategies that align technological strengths with user needs and therapeutic priorities.

Mapping how regional regulatory regimes, talent concentrations, and infrastructure realities influence deployment choices, partnerships, and collaboration models globally

Regional dynamics are shaping how organizations deploy informatics solutions and structure partnerships, with each geography presenting distinct regulatory landscapes, talent pools, and infrastructure considerations. In the Americas, strong investment in translational research, a deep concentration of biopharma headquarters, and established cloud and HPC capacity combine to favor rapid adoption of integrated bioinformatics and cheminformatics platforms. This environment supports complex collaborations between academic centers and commercial partners, and it places a premium on interoperability and vendor ecosystems that can support end-to-end discovery workflows across diverse institutions.

Europe, the Middle East, and Africa present a heterogeneous mix of regulatory regimes and research ecosystems. In parts of Europe, stringent data protection and regional research funding frameworks encourage hybrid deployment models and strong emphasis on data governance. Meanwhile, pockets of innovation across the region drive demand for localized expertise and integration services that can adapt global platforms to regional research priorities. In the Asia-Pacific region, rapid expansion of biotech activity, sizable talent pools in computational biology and chemistry, and policy initiatives that prioritize innovation have catalyzed adoption of cloud-native solutions and public-private partnerships. However, organizations in this region also emphasize cost-efficiency and scalable deployment models that can accommodate fast-growing research portfolios. Across all regions, cross-border collaborations and virtualized research networks are increasing, creating new imperatives for standardized data exchange, compliance, and secure collaboration practices.

Profiling how platform vendors, integrators, service providers, and research partners are organizing capabilities and alliances to deliver end-to-end discovery solutions

Companies operating in the drug discovery informatics space exhibit differentiated capabilities across platform development, service delivery, and integrative partnerships. Established software vendors focus on building robust, validated toolchains for bioinformatics and cheminformatics, investing in modular architectures that enable customers to combine genomic, proteomic, and molecular modeling outputs. Simultaneously, a growing cohort of specialized firms leverages machine learning and physics-informed models to enhance predictive performance in ADMET prediction, virtual screening, and structure-based design, often partnering with larger integrators to reach enterprise customers.

Service-oriented organizations, including consulting firms and systems integrators, play a pivotal role in helping end users translate platform capabilities into operational workflows. These providers are extending offerings beyond tactical implementation to include model governance, data harmonization, and continuous performance monitoring. Contract research organizations are increasingly embedding informatics capabilities into trial and preclinical workflows, while academic spinouts contribute novel algorithms and domain expertise that accelerate scientific breakthroughs. Strategic alliances between platform vendors, cloud providers, and CROs are becoming more common, enabling bundled offerings that reduce integration friction for customers. Observed across the ecosystem is an emphasis on open interfaces, standardized data models, and partnership structures that distribute risk while preserving the capacity for rapid innovation.

Practical strategic moves for leaders to build interoperable platforms, balance deployment risks, and strengthen model governance to accelerate discovery pipelines

Industry leaders should pursue a set of pragmatic, high-impact actions to align organizational capabilities with emerging informatics demands and to protect strategic flexibility. First, prioritize interoperable architectures and standardized data models so that new tools can be integrated without extensive reengineering; this reduces vendor lock-in and accelerates cross-functional workflows. Second, adopt a hybrid deployment strategy that balances the security and control of on-premise resources with the elastic compute and collaboration benefits of cloud environments. This approach allows teams to allocate sensitive data workflows to controlled environments while leveraging public cloud for compute-intensive simulations.

Third, strengthen supplier diversification and contractual mechanisms to manage geopolitical and tariff-related risks. Include clauses that address cost adjustments and delivery contingencies, and cultivate regional supplier relationships where appropriate. Fourth, invest in workforce development by combining computational training for wet-lab scientists with domain education for data engineers, building multidisciplinary teams capable of iterating rapidly between models and experiments. Fifth, establish robust model governance frameworks that encompass validation protocols, provenance tracking, and performance monitoring, ensuring reproducibility and regulatory readiness. Finally, pursue targeted partnerships with academic centers and CROs to access specialized assays and validation pathways, thereby shortening the route from in silico prediction to empirically supported candidate progression.

Explaining the mixed-method research approach that integrates stakeholder interviews and secondary analysis to produce validated insights and transparent limitations

The research methodology underpinning this analysis combined multi-source qualitative inquiry with structured synthesis to produce defensible, actionable insights. Primary research included interviews with key stakeholders across pharmaceutical and biotechnology companies, contract research organizations, platform vendors, and academic research groups, focusing on procurement behavior, deployment decisions, integration challenges, and therapeutic area priorities. These engagements were designed to capture practitioner perspectives on capabilities, pain points, and strategic tradeoffs, and interview participants represented computational scientists, R&D leaders, and operations managers.

Secondary research reviewed technical literature, vendor documentation, and publicly available case studies to contextualize practitioner testimony and to validate technical trends. Data synthesis emphasized triangulation: where multiple independent sources converged on similar findings, confidence in the insight increased. Segmentation was applied along component, application, deployment, end-user, and therapeutic area dimensions to reflect how capabilities and demand differ across use cases. Limitations of the methodology include potential selection bias in stakeholder participation and the rapid pace of technological change that can outdate specific tool-level details; to mitigate these risks, the approach prioritized thematic patterns and structural dynamics that are robust across vendors and geographies. Ethical considerations guided the research, including anonymization of interview responses and adherence to consent protocols for proprietary information.

Concluding insights that synthesize methodological, commercial, and operational drivers shaping the future of computational discovery and translational research

The cumulative analysis highlights a field in motion: methodological advances, platform maturation, and shifting commercial dynamics are converging to reshape how drug discovery is conceptualized and executed. Informatics capabilities are no longer auxiliary tools but central enablers of hypothesis generation and candidate progression, and the interplay between software platforms and services determines the degree to which organizations can operationalize computational insights. Regional and tariff-driven commercial factors introduce practical constraints that influence procurement choices and deployment architectures, while segmentation by application and therapeutic area clarifies where investments will yield the greatest scientific and operational returns.

For research leaders and commercial strategists, the imperative is clear: prioritize modular, governed informatics ecosystems that support reproducibility, integrate with laboratory operations, and scale across deployment scenarios. By aligning talent, governance, and partnership strategies with technological advances, organizations can convert computational promise into experimentally validated therapeutics. Ultimately, success hinges on the ability to maintain scientific rigor while adopting adaptive procurement and deployment practices that absorb commercial volatility and accelerate translational progress.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drug Discovery Informatics Market, by Component

  • 8.1. Services
    • 8.1.1. Consulting
    • 8.1.2. Integration
    • 8.1.3. Support And Maintenance
  • 8.2. Software
    • 8.2.1. Bioinformatics
      • 8.2.1.1. Genomics Informatics
      • 8.2.1.2. Proteomics Informatics
      • 8.2.1.3. Transcriptomics Informatics
    • 8.2.2. Cheminformatics
      • 8.2.2.1. Molecular Docking
      • 8.2.2.2. Qsar Modeling
      • 8.2.2.3. Virtual Screening

9. Drug Discovery Informatics Market, by Therapeutic Area

  • 9.1. Cardiovascular Diseases
  • 9.2. Infectious Diseases
  • 9.3. Metabolic Disorders
  • 9.4. Neuroscience
  • 9.5. Oncology

10. Drug Discovery Informatics Market, by Application

  • 10.1. Admet Prediction
    • 10.1.1. Metabolism Prediction
    • 10.1.2. Pharmacokinetics Prediction
    • 10.1.3. Toxicity Prediction
  • 10.2. Lead Discovery
    • 10.2.1. High Throughput Screening Informatics
    • 10.2.2. Hit To Lead Informatics
    • 10.2.3. Virtual Screening Informatics
  • 10.3. Molecular Modeling Simulation
    • 10.3.1. Molecular Dynamics
    • 10.3.2. Qsar Modeling
    • 10.3.3. Structure Based Design
  • 10.4. Target Identification
    • 10.4.1. Genomic Analysis
    • 10.4.2. Proteomic Analysis
    • 10.4.3. Target Validation Informatics

11. Drug Discovery Informatics Market, by End User

  • 11.1. Academic Research Institutes
  • 11.2. Contract Research Organizations
  • 11.3. Pharmaceutical Biotechnology Companies

12. Drug Discovery Informatics Market, by Deployment

  • 12.1. Cloud
  • 12.2. On Premise

13. Drug Discovery Informatics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Drug Discovery Informatics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Drug Discovery Informatics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Drug Discovery Informatics Market

17. China Drug Discovery Informatics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. BioSolveIT GmbH
  • 18.6. Certara, Inc.
  • 18.7. Clarivate PLC
  • 18.8. Dassault Systemes SE
  • 18.9. Dotmatics Ltd
  • 18.10. Genedata AG
  • 18.11. InSilico Medicine
  • 18.12. International Business Machines Corporation
  • 18.13. Jubilant Biosys Ltd.
  • 18.14. Optibrium Ltd
  • 18.15. Oracle Corporation
  • 18.16. PerkinElmer Inc.
  • 18.17. Schrodinger, Inc.
  • 18.18. TIBCO Software Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DRUG DISCOVERY INFORMATICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COMPONENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY DEPLOYMENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES DRUG DISCOVERY INFORMATICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA DRUG DISCOVERY INFORMATICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CONSULTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CONSULTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CONSULTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY INTEGRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY INTEGRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY INTEGRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SUPPORT AND MAINTENANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SUPPORT AND MAINTENANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SUPPORT AND MAINTENANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY GENOMICS INFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY GENOMICS INFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY GENOMICS INFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PROTEOMICS INFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PROTEOMICS INFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PROTEOMICS INFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TRANSCRIPTOMICS INFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TRANSCRIPTOMICS INFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TRANSCRIPTOMICS INFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR DOCKING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR DOCKING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR DOCKING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY QSAR MODELING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY QSAR MODELING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY QSAR MODELING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY VIRTUAL SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY VIRTUAL SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY VIRTUAL SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY NEUROSCIENCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY NEUROSCIENCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY NEUROSCIENCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY METABOLISM PREDICTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY METABOLISM PREDICTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY METABOLISM PREDICTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PHARMACOKINETICS PREDICTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PHARMACOKINETICS PREDICTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PHARMACOKINETICS PREDICTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TOXICITY PREDICTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TOXICITY PREDICTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TOXICITY PREDICTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HIGH THROUGHPUT SCREENING INFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HIGH THROUGHPUT SCREENING INFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HIGH THROUGHPUT SCREENING INFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HIT TO LEAD INFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HIT TO LEAD INFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HIT TO LEAD INFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY VIRTUAL SCREENING INFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY VIRTUAL SCREENING INFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY VIRTUAL SCREENING INFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR DYNAMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR DYNAMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR DYNAMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY QSAR MODELING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY QSAR MODELING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY QSAR MODELING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY STRUCTURE BASED DESIGN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY STRUCTURE BASED DESIGN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY STRUCTURE BASED DESIGN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY GENOMIC ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY GENOMIC ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY GENOMIC ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET VALIDATION INFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET VALIDATION INFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET VALIDATION INFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CLOUD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CLOUD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CLOUD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ON PREMISE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ON PREMISE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ON PREMISE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE DRUG DISCOVERY INFORMATICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE DRUG DISCOVERY INFORMATICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE DRUG DISCOVERY INFORMATICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE DRUG DISCOVERY INFORMATICS MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST DRUG DISCOVERY INFORMATICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST DRUG DISCOVERY INFORMATICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST DRUG DISCOVERY INFORMATICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST DRUG DISCOVERY INFORMATICS MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 245. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN DRUG DISCOVERY INFORMATICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN DRUG DISCOVERY INFORMATICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 254. ASEAN DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN DRUG DISCOVERY INFORMATICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN DRUG DISCOVERY INFORMATICS MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 260. GCC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 261. GCC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 262. GCC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 263. GCC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 264. GCC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 265. GCC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 266. GCC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 267. GCC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 268. GCC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 269. GCC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 270. GCC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, 2018-2032 (USD MILLION)
  • TABLE 271. GCC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 272. GCC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. GCC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPEAN UNION DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPEAN UNION DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPEAN UNION DRUG DISCOVERY INFORMATICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION DRUG DISCOVERY INFORMATICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPEAN UNION DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPEAN UNION DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPEAN UNION DRUG DISCOVERY INFORMATICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION DRUG DISCOVERY INFORMATICS MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 288. BRICS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 289. BRICS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 290. BRICS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 291. BRICS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 292. BRICS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 293. BRICS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 294. BRICS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 295. BRICS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 296. BRICS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 297. BRICS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 298. BRICS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, 2018-2032 (USD MILLION)
  • TABLE 299. BRICS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 300. BRICS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 301. BRICS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)